Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

BACKGROUND: Cystic Fibrosis (CF) is a life-shortening genetic disease in which ~80% of deaths result from loss of lung function linked to inflammation due to chronic bacterial infection (principally Pseudomonas aeruginosa). Pulmonary exacerbations (intermittent episodes during which symptoms of lung...

Descripción completa

Detalles Bibliográficos
Autores principales: VanDevanter, Donald R, O'Riordan, Mary A, Blumer, Jeffrey L, Konstan, Michael W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959026/
https://www.ncbi.nlm.nih.gov/pubmed/20925941
http://dx.doi.org/10.1186/1465-9921-11-137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959026/
https://www.ncbi.nlm.nih.gov/pubmed/20925941
http://dx.doi.org/10.1186/1465-9921-11-137

Ejemplares similares